Analysts/Institutional Investor Meet/Con. Call Updates

21st August, 2026 To, To, The General Manager The Manager, Department of Corporate Services Listing Department, BSE Ltd. National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, “Exchange Plaza”, C-1, Block G, Dalal Street, Bandra-Kurla Complex, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Ref.: Scrip Code No. : 540701 (Equity) Ref. : (i) Symbol – DCAL : 975834, 976560, 977467, 977859 and (ii) Series – EQ 978062 (Debt) SUB: TRANSCRIPT OF EARNINGS CONFERENCE CALL - QUARTER ENDING 30TH JUNE, 2026 Dear Sir, Pursuant to Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, pls. find enclosed herewith transcript of earnings conference call arranged by the Company with Investors on Monday, 17th August, 2026 to discuss the financial result and performance of the Company for the quarter ended on 30th June, 2026. The aforesaid transcript is also being hosted on the website of the Company, www.imdcal.com in accordance with the Regulations 46 and 62 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. Kindly take the same on your record. Thanking You, Yours faithfully, For, Dishman Carbogen Amcis Limited Shrima Dave Company Secretary Encl.: As above Dishman Carbogen Amcis Limited Earnings Conference Call Transcript Event: Dishman Carbogen Amcis Limited – First Quarter Ending June 30, 2026 Earnings Call Event Date/Time: August 17, 2026/ 1700 HRS Dishman Carbogen Amcis Limited Conference Call – August 17, 2026 CORPORATE PARTICIPANTS Harshil Dalal Global CFO - Dishman Carbogen Amcis Limited Mr. Paolo Armanino Chief Operating Officer - Dishman Carbogen Amcis Limited Mr. Stephan Fritschi Chief Executive Officer - CARBOGEN AMCIS entities, Company’s wholly owned subsidiaries Ms. Angela Ameriks Chief Commercial Officer Republished with permission. No part of this publication may be reproduced or transmitted in any form or by any means without the prior written consent of Dishman Carbogen Amcis Limited. Dishman Carbogen Amcis Limited Conference Call – August 17, 2026 Moderator Good evening, ladies and gentlemen, I am Akash, moderator for the conference call. Welcome to Dishman Carbogen Amcis Limited Q1 FY27 Earnings Conference Call. We have with us today, Mr. Stephan Fritschi, Chief Executive Officer (Carbogen Amcis); Mr. Harshil Dalal, Global Chief Financial Officer; Mr. Paolo Armanino, Chief Operating Officer, India; Ms. Angela Ameriks, Chief Commercial Officer; and Ms. Krishna Patel from EY. Asa a reminder, all participants will be in listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during your conference call, please signal an operator by pressing * and then 0 on your touch-tone telephone. Please note this conference is being recorded. I would now like to hand over the floor to Mr. Stephan Fritschi. Thank you and over to you sir. Stephan Fritschi Thank you very much. Welcome, everybody, to today's investor call to talk about the Q1 FY26-27 financial results. As you heard, this is Stephan Fritschi. I'm the CEO of Carbogen Amcis. Before we go into the financials, I would like to give some brief operational update about Carbogen Amcis, followed by Paolo's update on Dishman Carbogen Amcis operations. But let's start with our sales activities, what we have done in the past three months. Quite some changes happened in this area. As you know, I mentioned this in the past, our slogan is, “Be close to the market, be close to the customers”. With this slogan in mind, we have hired a new Global Chief Commercial Officer, namely Angela Ameriks. I'm very happy to introduce her, and she will address some words to you at the end of this presentation. She brings decades of experience in the CDMO business. She was working for highly recognized CDMOs in the past and brings a remarkable network into our organization. A new sales leadership team has been hired for India as well. This intensifies our focus on our sales activities. We continue to strengthen our sales force remarkably, and we will keep doing this. All this in mind, we want to be more agile and more active on the market. Some other keynotes. Our SPRINT initiative, you might remember, the SPRINT is our initiative to acquire early phase projects in Carbogen Amcis, is quite successful. It resulted in positive results, and some nice and promising projects could be acquired. Also, the packaged drug substance product is being continued to be promoted. It's of high interest from our customer sites, especially in the field of the bioconjugation space. Last but not least, close interaction between Dishman Carbogen Amcis and Carbogen Amcis is intensively increased and promoted, and shows some good successes in the market. Multiple processes are being transferred from Carbogen to Dishman in India. Customers will benefit from lower prices, but still get the high quality as usual. Republished with permission. No part of this publication may be reproduced or transmitted in any form or by any means without the prior written consent of Dishman Carbogen Amcis Limited. Dishman Carbogen Amcis Limited Conference Call – August 17, 2026 Generally spoken, the order income is picking up, also market pressure is still existing. Let's come to our business units, let me share some words about this, starting with our French subsidiary, the drug product, which is located in Saint-Beauzire. We are more recognized in the drug product market, hence more RFPs are obtained. Also, market shows some challenges, but still, we could increase our quotation rates. Some new projects could be acquired during the last quarter. Some big pharma audits occurred with very positive outcome. This is very promising, and we are confident that we can get into more business with also these big pharmas. Still in parallel, we keep our cost control rigorously pursued. Drug substance, we could successfully transform multiple Phase II projects into late phase programs. More than 10 late phase projects, including PPQ campaigns, are now in our portfolio, actually more than 13. Among normal APIs, also ADC related molecules with higher priority status at the FDA are secured. This is important for future commercial product supply. Also, inspections are scheduled for later this year. More information to be communicated once it happens. Recently, a new commercial product from the big pharma has been approved by the U.S. FDA, which adds another commercial product to our portfolio. The co-investment with our Japanese clients is proceeding nicely and it's on track. We're still expecting operational to be in the course of next year. The specialty, that's our cholesterol and Vitamin D and analogues business, has nicely developed in the first quarter, especially the VDA, the Vitamin D and the analogues business, has increased its sales, but also the margin, which is very good news for us. Also, we got new Wool grease sources with more attractive prices, which could be accessed, and we are confident that this will continue talking to different suppliers. Still, the cost reduction programs across this business unit are still ongoing and result their first signs. New markets for cholesterol, but also Vitamin D and derivatives are accessed and penetrated, for example, in Vietnam, in Africa, South America, etc. Last but not least, the collaboration with Dishman Carbogen Amcis is very important and it gets increased importance. Numerous transfer activities have been initiated with the goal to produce the corresponding commercial products in India to the benefit of our customers, but also to guarantee higher margins for our group. This is what we call active life cycle management of commercial products. That's an ongoing effort. With this, I would like to hand over to Paolo, who gives you more information about our Indian operations. Paolo Armanino Thank you, Stephan, and good afternoon to all the shareholders. I would [Showing first 8,000 characters — download PDF for full document]